ETFs

Biotech ETFs Hold Up as Hims-Lilly GLP-1 Pact and Summit's FDA Verdict Near

Biotech ETFs are outperforming the broader market ahead of a Nov. 14 FDA target date for Summit Therapeutics' ivonescimab plus chemotherapy in…

U2Fx.comU2Fx.com
Nov 9, 2026 - 22:00
 0  0
Biotech ETFs Hold Up as Hims-Lilly GLP-1 Pact and Summit's FDA Verdict Near
Biotech ETFs are outperforming the broader market ahead of a Nov. 14 FDA target date for Summit Therapeutics' ivonescimab plus chemotherapy in…
Read More

Tags:

Previous Article

QUICK SPARK: Canary Capital Launches Staked INJ ETF With Yield Potential

Next Article

Bitcoin ETFs shed $1.3B in biggest weekly outflow since late June

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

U2Fx.com
U2Fx.com

Related Posts

Monthly Spotlight: ETFs

Monthly Spotlight: ETFs

U2Fx.com Sep 2, 2026  0  20

U2Fx.com Oct 20, 2026  0  15

Roundhill T-REX 2X Long DRAM Daily Target ETF (RAM) Debuts with Largest Day-One Trading Volume of Any U.S.-Listed Leveraged or Inverse ETF

Roundhill T-REX 2X Long DRAM Daily Target ETF (RAM) Deb...

U2Fx.com Jun 29, 2026  0  25